Native peptide mapping

New method to monitor Higher Order Structure changes in a QC laboratory

Michel Degueldre – ASB PCMD1

7th International Symposium on Higher Order Structure of Protein Therapeutics *Providence, RI* USA





- 1. Context
- 2. Development stage
 - I. Feasibility assessment
 - II. Case study I IgG4 analysis and bioassay relationship
- 3. QC applicability
 - I. Case study II IgG1 analysis and bioassay relationship
- 4. Conclusions and perspective

1. Context

- 2. Development stage
 - I. Feasibility assessment
 - II. Case study I IgG4 analysis and bioassay relationship
- 3. QC applicability
 - I. Case study II IgG1 analysis and bioassay relationship
- 4. Conclusions and perspective

Importance of monitoring conformational changes

Sensitive to temperature, pH, Oxidative stress, agitation, light exposure,...





Changes in protein structure - Impact on : stability, specificity and activity

"Stability indicating" methods = Pool of physico/chemical & bioassay methods Regulatory requirement



May be a risk for the patient ?

Analytical and structural characterization package for mAbs⁵

Higher-order structure

- Circular Dichroism
- X-Ray Structure
- NMR
- Epitope Detection
- Specific Binding
- FTIR

Structure / Sequence

- N- and C-terminus
- Amino Acid Analysis
- Peptide Mapping and Sequencing
- Monosaccharide Analysis
- Oligosaccharide Mapping
- Mass Spectrometry
- Disulphide linkage
 - Identity
 - N-Terminal Sequence

Assay

OD, HPLC, AAA, Biacore,

ELISA, IFMA, Bradford,

Lowry, Bioassay

- Peptide Mapping
- Specific Bioassay
- IEF
- HPLC

Activity

- Bioassay in vivo and in vitro
- Specific binding assay
- Gene reporter assay (immunogenicity)

Size & Aggregation

- SE-HPLC (also identity and assay)
- SDS PAGE / Bioanalyser

– AUC

– AF4

– LLS

Purity

- RP-HPLC
- SE-HPLC
- Peptide mapping
- SDS-PAGE
 - Field Flow Fractionation
- Elisa (HCP)
- Immunoblot
- DNA assay
- LAL test
- Virus test

Surface charge

- IEF
- CZE
- IEX-HPLC
- iCE280
- Chromatofocusing



Carbohydrate analysis

ESI-MS (whole molecule)

MALDI-TOF (released carboh.)

Separation of labelled released

carbohydrates (2-AA, 2-AB)

urt

From characterization lab to QC lab...

Current situation...

Characterization

- Circular dichroism
- Ion mobility
- X-Ray structure
- NMR
- H/DX
- SPR
- FTIR

QC requirements

- Affordable equipment cost
- Simple data interpretation Yes or No
- Validated and robust methods designed for long-term use (>10 years)
- Generalist operators
- High throughput and speed essential

These current HOS monitoring methods are not easily amenable to a QC environment.

UCB proposal to monitor HOS in QC environment: Native peptide mapping

1. Context

- 2. Development stage
 - I. Feasibility assessment
 - II. Case study I IgG4 analysis and bioassay relationship
- 3. QC applicability
 - I. Case study II IgG1 analysis and bioassay relationship
- 4. Conclusions and perspective







Trypsin enzyme – cleaves specifically after K and R residues

First development on IgG4 mAb

MALDI-MS identification

Trypsin autolysis peaks but also...



9

Т1

First peptide is observed at first time point



First development on IgG4 mAb

MALDI-MS identification

Trypsin autolysis peaks but also...





10

Τ2

Second peptide is observed after several minutes...



90°

11

T2



12 T1

Repeatability assessment n=3



- 1. Context
- 2. Development stage
 - I. Feasibility assessment
 - II. Case study I IgG4 analysis and bioassay relationship
- 3. QC applicability
 - I. Case study II IgG1 analysis and bioassay relationship
- 4. Conclusions and perspective

Are we able to observe conformational changes¹⁴ between unstressed and stressed samples ?



Unstressed vs stressed samples

By this method, we are able to distinguish differences between unstressed and stressed samples. ... to distinguish conformational changes.

15





Is the biological activity impacted by the Τ1 stress? Oxidative **Temperature** Unstressed sample Acid stressed sample stressed sample stressed sample Complementary determining regions (CDR) Try to correlate structure (native pepmap) and function (CBA) 0.4 0.01 0.1 (µg/mL)

Do we observe differences between each stress conditions ?



urb



18

Τ1

Case study I – IgG4 analysis and bioassay relationship – Conclusions

This new method allows to:

- Detect HOS changes by comparing the samples to an unstressed sample
 - Results confirmed by well-established orthogonal technique (CD)
- Investigate structure activity relationship



Do we observe differences between each stress conditions ?



T1

- 1. Context
- 2. Development stage
 - I. Feasibility assessment
 - II. Case study I IgG4 analysis and bioassay relationship
- 3. QC applicability
 - I. Case study II IgG1 analysis and bioassay relationship
- 4. Conclusions and perspective

From development stage to QC applicability From qualitative results to quantitative results



separation

QDa mass detector Peptides quantitation

Acouityees

Follow each peptide thanks to the peptide list determined by MALDI-MS
→ SIR acquisition

SIR: Single Ion Recording

- Less expensive than MALDI-MS platform
- More user-friendly interface
- Need less MS expertise to use it
- Managed by CDS GMP compliance

« QC friendly system »



Method development – Native peptide mapping data vs Cell-based assay Quantitative data of IgG1 stressed sample



Method development – Native peptide mapping data vs ELISA binding Quantitative data of IgG1 stressed sample



Samples	%RP ELISA
50°C	Not comp
pH3	Not comp

κ-light chain region is impacted by stresses Hypothesis

Miss-binding » of the revelation Ab during the ELISA testing
Explain the non-comparability between samples and ref std



- 1. Context
- 2. Development stage
 - I. Feasibility assessment
 - II. Case study I IgG4 analysis and bioassay relationship
- 3. QC applicability
 - I. Case study II IgG1 analysis and bioassay relationship
- 4. Conclusions and perspective

To summarize...

Native peptide mapping:

- Is a **QC-friendly method able to monitor** HOS change for several (4) mAbs.
- May allow correlation of protein conformational changes with biological activity

For the future...

- Generate **more data** to support the use of native peptide mapping to monitor HOS changes and structure-activity relationships
- Evaluate the utility of **native peptide mapping** as a stability indicating method

Special thanks to all our colleagues on this journey:

- Characterization team ASB
- PCMD1 team ASB
- Bioassay Dev.Team- ASB
- And especially:

Michael Knight	Oliver Durrant		
Julie Braun	Elizabeth Rodriguez		
Eglantine Girot	Will Burkitt		
Erica Bortolotto	Jennifer Halley		
Sandrine Van Leugenhaeghe			
Maria-Teresa Chiusano			
Gaël Debauve	Annick Gervais	John O'Hara	
	Carl Jone		

Thanks!

Questions?